论文部分内容阅读
目的观察紫杉醇联合索菲拉尼治疗中晚期肝癌的临床疗效及安全性。方法将82例中晚期肝癌患者随机分为对照组41例和试验组41例。对照组予以静脉注射50 mg·m~(-2)紫杉醇,第1天;试验组予以静脉注射50mg·m~(-2)紫杉醇,第1天+口服索菲拉尼400 mg,bid。2组患者一个疗程为28 d,共治疗2个疗程。比较2组患者的临床疗效、生活质量改善情况、中位生存期、治疗前后肝功能变化以及不良反应情况。结果治疗后,试验组的客观有效率和临床获益率均明显优于对照组(58.54%vs 31.71%,87.80%vs 56.10%,P<0.05)。治疗后,试验组的生活质量改善率明显优于对照组(75.61%vs 36.59%,P<0.05)。治疗后,试验组的中位生存期为15.8个月显著长于对照组的9.4个月(P<0.05)。治疗后,2组患者的肝功能指标均较治疗前明显恶化。2组患者不良反应发生情况比较差异无统计学意义(P<0.05)。结论紫杉醇联合索拉非尼治疗中晚期肝癌的临床疗效显著优于单纯使用紫杉醇,且能显著延长患者的中位生存期。
Objective To observe the clinical efficacy and safety of paclitaxel combined with sofenilanic in the treatment of advanced hepatocellular carcinoma. Methods 82 patients with advanced liver cancer were randomly divided into control group 41 cases and experimental group 41 cases. The control group received intravenous injection of paclitaxel (50 mg · m -2) on the first day. The experimental group received intravenous injection of paclitaxel (50 mg · m -2) and on the first day + 400 mg of sorafenib. Two groups of patients for a course of 28 days, a total of 2 courses of treatment. The clinical efficacy, quality of life, median survival, changes in liver function before and after treatment, and adverse reactions were compared between the two groups. Results After treatment, the objective and clinical benefits of the experimental group were significantly better than those of the control group (58.54% vs 31.71%, 87.80% vs 56.10%, P <0.05). After treatment, the quality of life improvement rate of the experimental group was significantly better than that of the control group (75.61% vs 36.59%, P <0.05). After treatment, the median survival time of the experimental group was 15.8 months significantly longer than that of the control group 9.4 months (P <0.05). After treatment, two groups of patients with liver function indicators were significantly worse than before treatment. There was no significant difference in adverse reactions between the two groups (P <0.05). Conclusion Paclitaxel combined with sorafenib in the treatment of advanced liver cancer clinical efficacy was significantly better than the simple use of paclitaxel, and can significantly prolong the median survival of patients.